Bristol-Myers Squibb wins US patent infringement trial against Gilead over Yescarta: report

A federal jury in the US has sided with Bristol-Myers Squibb in a patent infringement trial against Gilead Sciences over the CAR-T cell therapy Yescarta (axicabtagene ciloleucel), Bloomberg reported Friday.

The jury in Los Angeles determined that Gilead owes Bristol-Myers Squibb $585 million in damages plus a 27.6% running royalty on sales of the CD19-directed genetically modified autologous T cell immunotherapy. Bristol-Myers Squibb reportedly calculated the royalty to be $167 million through the trial.

Gilead, which gained Yescarta through its $11.9-billion acquisition of Kite Pharma in 2017, said it will appeal the verdict.

Yescarta was approved by the FDA later that year for certain patients with large B-cell lymphoma.


To read more Top Story articles, click here.